In HepG2 cells, 7.5 µM AKT inhibitor VIII for 14 h increased LDLR mRNA and LDLR promoter reporter activity relative to vehicle. A separate transcription-block experiment found similar LDLR mRNA decay, with reported half-lives of 2 h 08 min for inhibitor-treated cells and 1 h 56 min for vehicle. Its inhibitor pretreatment conditions are ambiguous in the published cross-reference. These findings support increased transcription rather than substantial mRNA stabilization in this model. [2]
AKT1 co-crystal defines an allosteric binding site
Biochemical assay · Purified human AKT1(1–443), lacking the C-terminal hydrophobic motif; PDB 3O96 [1]
The ligand occupies the PH/kinase-domain interface in an inactive conformation.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.25 mM inhibitor with 4.7 mg/mL AKT1(1–443)
- Method
- Co-crystallization and X-ray structure determination
- Reported limits
- A crystallization concentration, not an IC50 or cellular treatment dose. Solvent composition for inhibitor stock is not specified in the crystallization section.
Methods and source locations
Compound reported in the paper: AKT inhibitor VIII (AKTI-1/2); Compound label in the paper: Inhibitor VIII
Evidence for the named research compound in the reported material and model; no Adooq lot validation or salt conversion.
Results; Figures 1, 3, 5B and Table 1; Materials and Methods: Crystallization and structural refinement
AKT1:Inhibitor VIII co-crystal diffraction: X-ray crystallography; one crystal dataset — Results; Table 1; X-ray data collection and refinement
Ligand binding position: Co-crystal structure — Results; Figures 3 and 5B
LDLR mRNA expression and promoter activity in HepG2 cells
Cell-based study · Human HepG2 cells; endogenous LDLR mRNA and LDLR-promoter luciferase reporter [2]
At 7.5 µM for 14 h, AKT inhibitor VIII increased LDLR mRNA and LDLR promoter reporter activity relative to vehicle.
Literature-Reported Treatment Conditions
- Treatment concentration
- 7.5 µM
- Exposure duration
- 14 h
- Method
- Addition to HepG2 cultures; reporter treatment started 24 h after transfection
- Vehicle
- 0.1% (v/v) DMSO; matched DMSO-only control
- Co-treatment
- None; other AKT inhibitors were separate comparator treatments.
- Reported limits
- Exact fold changes are not extracted from plotted bars.
Methods and source locations
Compound reported in the paper: AKT inhibitor VIII (AKTI-1/2); Compound label in the paper: AKT inhibitor VIII
Evidence for the named research compound in the reported material and model; no Adooq lot validation or salt conversion.
Figure 2A–B and caption; Reagents and antibodies; Cell cultures; qPCR; reporter assay methods
LDLR mRNA normalized to GAPDH: qPCR; technical duplicates; 2^−ΔΔCt; Fig 2 caption reports 95% confidence intervals — Figure 2A and caption; Quantitative real-time PCR
LDLR promoter-driven firefly luciferase normalized to Renilla: Dual-luciferase reporter assay; Fig 2 caption reports 95% confidence intervals — Figure 2B and caption; Plasmids, transfection and reporter assay
LDLR mRNA decay after transcription blockade
Cell-based study · Human HepG2 cells, vehicle or AKT inhibitor VIII pretreatment followed by actinomycin D [2]
LDLR mRNA decayed similarly to vehicle; reported half-life estimates were close.
Literature-Reported Treatment Conditions
- Exposure duration
- Samples at 0, 2, 4 and 6 h after actinomycin D
- Method
- qPCR after transcription blockade; each condition normalized to its pre-ActD value
- Vehicle
- Matched vehicle; shared cell methods specify 0.1% (v/v) DMSO
- Co-treatment
- Actinomycin D, 5 µg/ml, used to block transcription; not a therapeutic combination.
- Reported limits
- Inhibitor concentration and pretreatment duration are not unambiguously recoverable: Fig 3 caption refers to nonexistent Fig 1A. Do not import the 7.5 µM/14 h conditions from Fig 2.
Methods and source locations
Compound reported in the paper: AKT inhibitor VIII (AKTI-1/2); Compound label in the paper: AKT inhibitor VIII
Evidence for the named research compound in the reported material and model; no Adooq lot validation or salt conversion.
Figure 3G–H and caption; Statistical analyses; Cell cultures
LDLR mRNA half-life after transcription inhibition: Least-squares regression of qPCR decay data; GAPDH-normalized; five independent experiments in decay panels — Figure 3G–H; Statistical analyses